ReviewActa neurologica Scandinavica2017
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.
Review in Acta neurologica Scandinavica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Findings on Magnetic Resonance Imaging in Neuroborreliosis-A Nationwide Cohort Study.European journal of neurology · 2026Article
- A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis.Brain communications · 2026Article
- Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study.Frontiers in neurology · 2025Article
- Determination of systemic inflammatory biomarkers in multiple sclerosis.Journal of medical biochemistry · 2024Article
- Multiple sclerosis imaging in clinical practice: a European-wide survey of 428 centers and conclusions by the ESNR Working Group.European radiology · 2023Article
- Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.Journal of neurology · 2023Article
- Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Observational
- A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.Frontiers in neurology · 2023Article
- The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey.Frontiers in neurology · 2023Article
- High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis.Frontiers in immunology · 2023Article
- Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Observational
- No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- [New MRI guidelines for multiple sclerosis].Der Radiologe · 2022Review
- Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.Frontiers in immunology · 2022Observational
- Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab.Neurology(R) neuroimmunology & neuroinflammation · 2020Observational
- Diagnosis and management of multiple sclerosis: MRI in clinical practice.Journal of neurology · 2020Article
- Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey.Multiple sclerosis and related disorders · 2020Article
- The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis.Journal of neurology · 2020Article
- Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is associated with inflammatory lesions in the brain and spinal cord. The detection of such inflammatory lesions using magnetic resonance imaging (MRI) is important in the consideration of the diagnosis and differential diagnoses of MS, as well as in the monitoring of disease activity and predicting treatment efficacy. Although there is strong evidence supporting the use of MRI for both the diagnosis and monitoring of disease activity, there is a lack of evidence regarding which MRI protocols to use, the frequency of examinations, and in what clinical situations to consider MRI examination. A national workshop to discuss these issues was held in Stockholm, Sweden, in August 2015, which resulted in a Swedish consensus statement regarding the use of MRI in the care of individuals with MS. The aim of this consensus statement is to provide practical advice for the use of MRI in this setting. The recommendations are based on a review of relevant literature and the clinical experience of workshop attendees. It is our hope that these recommendations will benefit individuals with MS and guide healthcare professionals responsible for their care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.